BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

H.C. Wainwright analyst Ed Arce affirms a Buy rating on shares of Inventiva (IVA) after the company announced the completion of patient ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeutics (GALT – Research Report) today. The company’s shares closed ...

Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

On Thursday, 27 March 2025, Nektar Therapeutics (NASDAQ: NKTR) participated in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The company provided a strategic ...